The speaker discusses the positive effects of certain diabetes drugs on reducing the risk of cancer and cardiovascular disease, highlighting the broadening focus in the biotech industry. They express frustration with the narrowing industry focus and high prices, emphasizing the importance of addressing the total market and meeting universal desires for happiness, psychedelics, and good health.
The Sunday Times' tech correspondent Danny Fortson brings on Christian Angermayer, founder of Apeiron Investments, to talk about psychedelics in Oregon (4:15), the spiritual experience of a “trip” (11:30), progressing toward the first FDA approval (15:30), how this will be introduced into the market (21:10), why having a qualified guide/therapist is critical (25:30), gaining societal acceptance (30:20), why he funded the longevity XPrize (34:20), the new approach to ageing (41:00), why we are on the cusp of a breakthrough in life span (42:30), the Ozempic effect (49:00, thriving in a toxic society (56:20), and how AI dovetails with psychedelics and longevity (1:01:50).
Hosted on Acast. See acast.com/privacy for more information.